Maplight concludes Phase I trial of schizophrenia and dyskinesia therapy

Maplight concludes Phase I trial of schizophrenia and dyskinesia therapy

Submitted by admin on August 19, 2022 - 10:38am
Source: 
Clinical Trials Arena
News Tags: 
Maplight Therapeutics
clinical trials
ML-007
schizophrenia
dyskinesia
Headline: 
Maplight concludes Phase I trial of schizophrenia and dyskinesia therapy
snippet: 

MapLight Therapeutics has concluded the Phase I clinical trial of ML-007 for treating neurologic ailments such as schizophrenia and dyskinesia.

Do Not Allow Advertisers to Use My Personal information